151 related articles for article (PubMed ID: 28945677)
1. Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.
Kobayashi R; Keino D; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
Pediatr Infect Dis J; 2018 May; 37(5):447-450. PubMed ID: 28945677
[TBL] [Abstract][Full Text] [Related]
2. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
[TBL] [Abstract][Full Text] [Related]
4. Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.
Okada N; Azuma M; Imanishi M; Zamami Y; Kirino Y; Nakamura T; Teraoka K; Abe M; Ishizawa K
Clin Ther; 2018 Feb; 40(2):252-260. PubMed ID: 29305017
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation.
Yasu T; Konuma T; Oiwa-Monna M; Kato S; Tanoue S; Isobe M; Mizusawa M; Kuroda S; Takahashi S; Tojo A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104271
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
7. Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: a nationwide observational study.
Ota Y; Obata Y; Takazono T; Tashiro M; Wakamura T; Takahashi A; Shiozawa Y; Miyazaki T; Nishino T; Izumikawa K
BMC Nephrol; 2021 Jun; 22(1):240. PubMed ID: 34193064
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
Javandoust Gharehbagh F; Roshanzamiri S; Farjami M; Hatami F; Lotfollahi L; Kazeminia N; Hatami F; Shokouhi S; Alavi Darazam I
J Oncol Pharm Pract; 2024 Jul; 30(5):919-929. PubMed ID: 38720564
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65 years old with hematological diseases.
Ueda S; Miyamoto S; Kaida K; Chizuka A; Kojima R; Takano J; Ogasawara T; Miyamoto K; Miyakoshi S; Kanda Y
J Infect Chemother; 2016 May; 22(5):287-91. PubMed ID: 26908230
[TBL] [Abstract][Full Text] [Related]
11. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.
Aversa F; Busca A; Candoni A; Cesaro S; Girmenia C; Luppi M; Nosari AM; Pagano L; Romani L; Rossi G; Venditti A; Novelli A
J Chemother; 2017 Jun; 29(3):131-143. PubMed ID: 28335692
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations.
Andrew EC; Curtis N; Coghlan B; Cranswick N; Gwee A
Br J Clin Pharmacol; 2018 May; 84(5):1006-1012. PubMed ID: 29352486
[TBL] [Abstract][Full Text] [Related]
14. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of renal effects of liposomal amphotericin B in children with malignancies with KDIGO and RIFLE criteria.
Devrim F; Çağlar İ; Acar SO; Akkuş Ş; Dinçel N; Yılmaz E; Tahta N; Demirağ B; Karapınar TH; Gözmen S; Oymak Y; Vergin C; Bayram N; Devrim İ
Nephrol Ther; 2021 Dec; 17(7):507-511. PubMed ID: 34535406
[TBL] [Abstract][Full Text] [Related]
16. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia.
Shigemi A; Matsumoto K; Ikawa K; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2011 Nov; 38(5):417-20. PubMed ID: 21885259
[TBL] [Abstract][Full Text] [Related]
17. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
Ural AU; Avcu F; Cetin T; Beyan C; Kaptan K; Nazaroglu NK; Yalcin A
Eur J Clin Pharmacol; 2002 Jan; 57(11):771-3. PubMed ID: 11868798
[TBL] [Abstract][Full Text] [Related]
19. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
20. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
